pharma · Pompe Disease (Late-onset) · Fabry Disease
Pacalis Therapeutics Pty
AMICUS THERAPEUTICS PTY LTD
Pacalis Therapeutics Pty clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- melbourne, AU
- Founded
- 2023
- Employees
- 1
- Programs
- 5
- Drugs
- 6
- Patents
- 0
Pacalis Therapeutics Pty projects
5 ClinicalTrials.gov programs sponsored by Pacalis Therapeutics Pty.
Pacalis Therapeutics Pty has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AT2221
AMICUS THERAPEUTICS PTY LTD
Pompe Disease (Late-onset)
1 trial -
AT2221, ATB200
AMICUS THERAPEUTICS PTY LTD
Adult Subjects With Late Onset Pompe Disease (LOPD)
1 trial -
Cipaglucosidase Alfa
AMICUS THERAPEUTICS PTY LTD
Pompe Disease (Late-onset)
1 trial -
Migalastat Hydrochloride Dispersible Tablet
AMICUS THERAPEUTICS PTY LTD
Fabry disease
1 trial -
migalastat HCl 150 mg
AMICUS THERAPEUTICS PTY LTD
Fabry Disease
1 trial
Frequently asked questions
How many clinical projects does Pacalis Therapeutics Pty have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.